INOVIS Capital GmbH: iThera Medical Receives Funding for Translating its Unique Imaging Technology into Clinical Practice
(firmenpresse) - INOVIS Capital GmbH / Key word(s): Finance/
INOVIS Capital GmbH: iThera Medical Receives Funding for Translating
its Unique Imaging Technology into Clinical Practice
DGAP-Media / 28.10.2011 / 20:17
---------------------------------------------------------------------
27 October 2011, Munich, Germany - iThera Medical, a spin-off from the
Helmholtz Zentrum München, has recently closed a Series A financing round
with BayBG Bayerische Beteiligungsgesellschaft mbH, and Mey Capital Matrix
GmbH, a Munich-based family office, as lead investor. Earlier this year,
the company also secured a Phase II grant from the GO-Bio programme, which
is funded by the German Ministry of Education and Research (BMBF) and
managed by Projektträger Jülich. iThera Medical will use the funds to
further develop and commercialize its technology for preclinical and
clinical applications.
iThera Medical builds on a unique multispectral optoacoustic imaging
technology invented by Prof. Dr Vasilis Ntziachristos and Dr Daniel
Razansky at the Helmholtz Zentrum München. It enables the non-invasive,
real-time visualization of anatomical, functional and molecular information
in living tissue, at depths and at a resolution not achievable by optical
imaging methods. The key advantage of the technology over other imaging
modalities is its unique combination of highly versatile optical contrast,
cross-sectional tissue imaging, and high temporal and spatial resolution.
In the space of one and a half years, iThera Medical has made significant
progress in product development. The company expects its first product, a
preclinical molecular imaging device, to reach the market in the near
future. Using multispectral optoacoustic tomography (MSOT), small animals
are precisely scanned in vivo and in real time. For the first time, the
biological effects of a drug can be monitored quantitatively at its site of
action in the body over a longer period of time. This not only improves the
quality of preclinical drug development dramatically, but also reduces the
duration and costs of biopharmaceutical drug development.
'We see great potential for iThera Medical's optoacoustic imaging
technology in preclinical research and clinical diagnostics. Their unique
technical advantage, together with competent management and an established
partnership with the Helmholtz Zentrum München, has convinced us of the
attractiveness of this project,' explains Peter Pauli, CEO of the BayBG
Bayerischen Beteiligungsgesellschaft mbH, Munich, commenting on the
decision to invest. In order to fully exploit the technology's potential
for many applications, iThera Medical has built a strong network of
collaboration partners in industry, academia and hospitals around the
globe.
'Our approach has met with an exceptional demand,' says Christian Wiest,
co-founder and CEO of iThera Medical. 'Together with our partners, we are
currently exploring potential applications in preclinical research and
clinical diagnostics, for example in the fields of cancer, cardiovascular
and neurological diseases.'
INOVIS Capital acted as an exclusive Corporate Finance adviser in this
transaction.
Contact for INOVIS Capital
Christian Wexlberger, CEO
T: +49 (0)89 452 352-116, E: wexlberger(at)inoviscapital.de
INOVIS Capital GmbH, Karlstraße 35, 80333 Munich, Germany
Contact for iThera Medical
Christian Wiest, CEO
T: +49 (0)89 318-3973, E: christian.wiest(at)ithera-medical.com
iThera Medical GmbH, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany
End of Media Release
---------------------------------------------------------------------
28.10.2011 Dissemination of a Press Release, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
144063 28.10.2011
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 28.10.2011 - 20:17 Uhr
Sprache: Deutsch
News-ID 81582
Anzahl Zeichen: 4969
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 324 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"INOVIS Capital GmbH: iThera Medical Receives Funding for Translating its Unique Imaging Technology into Clinical Practice"
steht unter der journalistisch-redaktionellen Verantwortung von
INOVIS Capital GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
